By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies and how to manage them, see our Privacy Policy.
EpiPen Logo

 

 

 

9 AUGUST 2018 UPDATE:


Availability of EpiPen® 0.3mg and EpiPen® JR 0.1.5mg Adrenaline Auto-Injectors

 

Latest Supply Status

Our manufacturing partner Meridian Medical Technologies, a Pfizer company, continues to experience interruptions in the production of EpiPen® 0.3mg and EpiPen® Jr 0.15mg Adrenaline Auto-Injectors. Throughout 2018, there has been intermittent supply at wholesalers, distributors and pharmacies in the UK. We are actively exploring several options with Pfizer that would help stabilize supply and will continue to provide updates, including timing for resolution, as we receive them from Pfizer.

We appreciate how important it is for individuals with life-threatening allergies to have access to epinephrine auto-injectors, and understand the challenges this situation continues to pose for patients.

We continue to maintain a stock management process for the distribution of EpiPen® 0.3mg Adrenaline Auto-Injectors and due to persistent manufacturing delays, this process will now be extended to EpiPen Jr® 0.15mg Adrenaline Auto-Injectors. Pharmacies are allocated product on a prescription-only basis and can place orders for up to a maximum of two EpiPen® 0.3mg or two EpiPen Jr® 0.15mg Adrenaline Auto-Injectors per prescription. It is important to note that supply of EpiPen® 0.3mg and EpiPen Jr® 0.15mg Adrenaline Auto-Injectors from Pfizer continues to vary and, as such, may not always be available for pharmacies to order.

Ongoing Supply Management

We are expediting shipments upon receipt from Pfizer. We also are working closely with Pfizer to stay informed of anticipated shipments and are maintaining regular dialogue with health authorities and patient associations to provide frequent updates on supply status.

Distribution of EpiPen® 0.3mg and EpiPen® Jr 0.15mg Auto-Injectors in the UK is being carefully monitored, in coordination with our UK distribution partner, Alliance Healthcare, to help manage product availability on an ongoing basis until a steady supply resumes. We will continue to proactively and diligently update pharmacies, healthcare professionals and patient advocacy groups across the country regarding any changes in stock availability. 

Information for Patients

Mylan is unable to make any specific treatment recommendation to individual patients. Patients should speak to their healthcare provider for appropriate actions to be taken. 

Information for Prescribers

To support patient access to the product during this supply constraint, we are encouraging healthcare professionals to manage prescription renewals diligently. Please note, when validating the expiry date of an adrenaline auto-injector, the product expires on the last day of the month indicated. For example, if it expires in October, it remains valid (not expired) until October 31.

Instructions for Pharmacists

Pharmacies that are presented with a prescription for EpiPen® 0.3mg or EpiPen® Jr 0.15mg Auto-Injectors are able to place an order for up to a maximum of two EpiPen® 0.3mg or EpiPen® Jr 0.15mg Auto-Injectors per prescription. Please send anonymized prescriptions for EpiPen® 0.3mg or EpiPen® Jr 0.15mg Auto-Injectors to Alliance Healthcare’s prescription validation service, either by Fax (0203 044 8996) or email (EOHotline@alliance-healthcare.co.uk). Please include your Alliance Healthcare account number when placing your order.

Contact Information

If you require additional information or have any questions, please contact Mylan Customer Services: +44(0) 1707 853 100.

Choose the right site for you

 

 

 

 

 

 

I AM A PATIENT I AM A MEMBER OF THE PUBLIC I AM A HEALTHCARE PROFESSIONAL

*These pages are intended only for patients prescribed an EpiPen®

EPI-2018-0218 DOP: August 2018